Targeting dysregulation of brain iron homeostasis in Parkinson's disease by iron chelators

Free Radical Biology and Medicine

Volumn 62, Issue , 2013, Pages 52-64

  Weinreb, Orly ^a   Mandel, Silvia ^a   Youdim, Moussa B H ^a   Amit, Tamar ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Brain; Free radicals; Iron; Iron chelation; Neuroprotection; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; AMINE OXIDASE (FLAVIN CONTAINING); ANTIOXIDANT; CATECHIN; CERULOPLASMIN; CLIOQUINOL; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; EPIGALLOCATECHIN GALLATE; FERRIPOX; GLUTATHIONE; HYPOXIA INDUCIBLE FACTOR 1; IRON; IRON CHELATING AGENT; LACTOFERRIN; MESSENGER RNA; NATURAL RESISTANCE ASSOCIATED MACROPHAGE PROTEIN 2; NEUROMELANIN; REACTIVE OXYGEN METABOLITE; TRANSFERRIN; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; BRAIN BLOOD VESSEL; BRAIN METABOLISM; ENZYME INHIBITION; HUMAN; IRON CHELATION; IRON METABOLISM; IRON OVERLOAD; IRON RESPONSIVE ELEMENT; IRON TRANSPORT; LIPID PEROXIDATION; MOLECULAR MECHANICS; MOLECULAR PATHOLOGY; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PHLEBOTOMY; PRIORITY JOURNAL; PROTEIN AGGREGATION; REVIEW; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA;

EID: 84884901205     PISSN: 08915849     EISSN: 18734596     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2013.01.017     Document Type: Review

References (230)

1. Bartzokis, G.; Sultzer, D.; Cummings, J.; Holt, L. E.; Hance, D. B.; Henderson, V. W.; Mintz, J. In vivo evaluation of brain iron in Alzheimer disease using magnetic resonance imaging. Arch. Gen. Psychiatry 57: 47-53; 2000. (Pubitemid 30035658)
2. Jellinger, K. A. The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease. Drugs Aging 14: 115-140; 1999. (Pubitemid 29086113)
3. Berg, D.; Gerlach, M.; Youdim, M. B.; Double, K. L.; Zecca, L.; Riederer, P.; Becker, G. Brain iron pathways and their relevance to Parkinson's disease. J. Neurochem. 79: 225-236; 2001. (Pubitemid 32988938)
4. Zecca, L.; Youdim, M. B. H.; Riederer, P.; Connor, J. R.; Crichton, R. R. Iron, brain ageing and neurodegenerative disorders. Nat. Rev. Neurosci. 5: 863-873; 2004. (Pubitemid 39482155)
5. Zecca, L.; Stroppolo, A.; Gatti, A.; Tampellini, D.; Toscani, M.; Gallorini, M.; Giaveri, G.; Arosio, P.; Santambrogio, P.; Fariello, R. G.; Karatekin, E.; Kleinman, M. H.; Turro, N.; Hornykiewicz, O.; Zucca, F. A. The role of iron and copper molecules in the neuronal vulnerability of locus coeruleus and substantia nigra during aging. Proc. Natl. Acad. Sci. USA 101: 9843-9848; 2004. (Pubitemid 38869324)
6. Smith, M. A.; Harris, P. L.; Sayre, L. M.; Perry, G. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc. Natl. Acad. Sci. USA 94: 9866-9868; 1997. (Pubitemid 27408156)
7. Smith, S. R.; Cooperman, S.; Lavaute, T.; Tresser, N.; Ghosh, M.; Meyron-Holtz, E.; Land, W.; Ollivierre, H.; Jortner, B.; Switzer 3rd R.; Messing, A.; Rouault, T. A. Severity of neurodegeneration correlates with compromise of iron metabolism in mice with iron regulatory protein deficiencies. Ann. N. Y. Acad. Sci. USA 1012: 65-83; 2004. (Pubitemid 38453516)
8. Hirsch, E. C. Altered regulation of iron transport and storage in Parkinson's disease. J. Neural Transm Suppl. 71: 201-204; 2006. (Pubitemid 351412121)
9. Smith, M. A.; Perry, G. Free radical damage, iron, and Alzheimer's disease. J. Neurol. Sci Suppl. 134: 92-94; 1995.
10. Halliwell, B. Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment. Drugs Aging 18: 685-716; 2001. (Pubitemid 32948277)
11. Sayre, L. M.; Smith, M. A.; Perry, G. Chemistry and biochemistry of oxidative stress in neurodegenerative disease. Curr. Med. Chem. 8: 721-738; 2001. (Pubitemid 32427903)
12. Pratico, D.; Delanty, N. Oxidative injury in diseases of the central nervous system: focus on Alzheimer's disease. Am. J. Med. 109: 577-585; 2000.
13. Przedborski, S. Programmed cell death in amyotrophic lateral sclerosis: a mechanism of pathogenic and therapeutic importance. Neurologist 10: 1-7; 2004. (Pubitemid 38140834)
14. Cheah, J. H.; Kim, S. F.; Hester, L. D.; Clancy, K. W.; Patterson 3rd S. E.; Papadopoulos, V.; Snyder, S. H. NMDA receptor-nitric oxide transmission mediates neuronal iron homeostasis via the GTPase Dexras1. Neuron 51: 431-440; 2006. (Pubitemid 44209322)
15. Halliwell, B. Oxidative stress and neurodegeneration: where are we now? J. Neurochem. 97: 1634-1658; 2006. (Pubitemid 43873658)
16. Benarroch, E. E. Brain iron homeostasis and neurodegenerative disease. Neurology 72: 1436-1440; 2009.
17. Crichton, R. R.; Dexter, D. T.; Ward, R. J. Brain iron metabolism and its perturbation in neurological diseases. J. Neural Transm. 118: 301-314; 2011.
18. Rausch, W. D.; Hirata, Y.; Nagatsu, T.; Riederer, P.; Jellinger, K. Tyrosine hydroxylase activity in caudate nucleus from Parkinson's disease: effects of iron and phosphorylating agents. J. Neurochem. 50: 202-208; 1988. (Pubitemid 18023500)
19. Rouault, T. A.; Cooperman, S. Brain iron metabolism. Semin. Pediatr. Neurol. 13: 142-148; 2006. (Pubitemid 44709651)
20. Moos, T.; Rosengren Nielsen, T.; Skjorringe, T.; Morgan, E. H. Iron trafficking inside the brain. J. Neurochem. 103: 1730-1740; 2007. (Pubitemid 350126643)
21. Madsen, E.; Gitlin, J. D. Copper and iron disorders of the brain. Annu. Rev. Neurosci. 30: 317-337; 2007. (Pubitemid 47224759)
22. Thompson, J. W.; Salahudeen, A. A.; Chollangi, S.; Ruiz, J. C.; Brautigam, C. A.; Makris, T. M.; Lipscomb, J. D.; Tomchick, D. R.; Bruick, R. K. Structural and molecular characterization of iron-sensing hemerythrin-like domain within F-box and leucine-rich repeat protein 5 (FBXL5). J. Biol. Chem. 287: 7357-7365; 2012.
23. Thompson, J. W.; Bruick, R. K. Protein degradation and iron homeostasis. Biochim. Biophys. Acta 1484-1490: 2012; 1823.
24. Salahudeen, A. A.; Thompson, J. W.; Ruiz, J. C.; Ma, H. W.; Kinch, L. N.; Li, Q.; Grishin, N. V.; Bruick, R. K. An E3 ligase possessing an iron-responsive hemerythrin domain is a regulator of iron homeostasis. Science 326: 722-726; 2009.
25. Vashisht, A. A.; Zumbrennen, K. B.; Huang, X.; Powers, D. N.; Durazo, A.; Sun, D.; Bhaskaran, N.; Persson, A.; Uhlen, M.; Sangfelt, O.; Spruck, C.; Leibold, E. A.; Wohlschlegel, J. A. Control of iron homeostasis by an iron-regulated ubiquitin ligase. Science 326: 718-721; 2009.
26. Olanow, C. W.; Stern, M. B.; Sethi, K. The scientific and clinical basis for the treatment of Parkinson disease. Neurology 72:S1-136; 2009. 2009.
27. Lorincz, M. T. Clinical implications of Parkinson's disease genetics. Semin. Neurol. 26: 492-498; 2006. (Pubitemid 44631071)
28. Lesage, S.; Brice, A. Parkinson's disease: from monogenic forms to genetic susceptibility factors. Hum. Mol. Genet 18:R48-59; 2009.
29. Hirsch, E. C. Biochemistry of Parkinson's disease with special reference to the dopaminergic systems. Mol. Neurobiol 9: 135-142; 1994.
30. Olanow, C. W. Early therapy for Parkinson's disease. Eur. Neurol. 32: 30-35; 1992.
31. Jellinger, K. A. Post mortem studies in Parkinson's disease - is it possible to detect brain areas for specific symptoms? J. Neural. Transm Suppl. 107: 1-29; 1991.
32. Jenner, P. Oxidative mechanisms in nigral cell death in Parkinson's disease. Mov. Disord 13: 24-34; 1998.
33. Jenner, P.; Olanow, C. W. Understanding cell death in Parkinson's disease. Ann. Neurol. 44:S72-84; 1998. (Pubitemid 28423832)
34. McNaught, K. S.; Jenner, P. Proteasomal function is impaired in substantia nigra in Parkinson's disease. Neurosci. Lett. 297: 191-194; 2001. (Pubitemid 32011306)
35. Youdim, M. B. H.; Ben-Shachar, D.; Riederer, P. Is Parkinson's disease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurodegeneration? Acta Neurol. Scand Suppl. 126: 47-54; 1989. (Pubitemid 20022076)
36. Gerlach, M.; Double, K. L.; Youdim, M. B.; Riederer, P. Potential sources of increased iron in the substantia nigra of Parkinsonian patients. J. Neural Transm. Suppl. 70: 133-142; 2006. (Pubitemid 44622190)
37. Gotz, M. E.; Double, K.; Gerlach, M.; Youdim, M. B.; Riederer, P. The relevance of iron in the pathogenesis of Parkinson's disease. Ann. N. Y. Acad. Sci. 1012: 193-208; 2004. (Pubitemid 38455479)
38. Riederer, P.; Sofic, E.; Rausch, W. D.; Schmidt, B.; Reynolds, G. P.; Jellinger, K.; Youdim, M. B. H. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J. Neurochem. 52: 515-520; 1989. (Pubitemid 19037617)
39. Youdim, M. B. H.; Riederer, P. The role of iron in senescence of dopaminergic neurons in Parkinson's disease. J. Neural Transm. Suppl. 40: 57-67; 1993. (Pubitemid 24005557)
40. Shoham, S.; Youdim, M. B. The effects of iron deficiency and iron and zinc supplementation on rat hippocampus ferritin. J. Neural Transm 109: 1241-1256; 2002.
41. Hirsch, E. C.; Brandel, J. P.; Galle, P.; Javoy-Agid, F.; Agid, Y. Iron and aluminum increase in the substantia nigra of patients with Parkinson's disease: an X-ray microanalysis. J. Neurochem. 56: 446-451; 1991. (Pubitemid 21901982)
42. Gorell, J. M.; Ordidge, R. J.; Brown, G. G.; Deniau, J. C.; Buderer, N. M.; Helpern, J. A. Increased iron-related MRI contrast in the substantia nigra in Parkinson's disease. Neurology 45: 1138-1143; 1995.
43. Berg, D.; Grote, C.; Rausch, W. D.; Maurer, M.; Wesemann, W.; Riederer, P.; Becker, G. Iron accumulation in the substantia nigra in rats visualized by ultrasound. Ultrasound Med. Biol. 25: 901-904; 1999. (Pubitemid 29325763)
44. Jellinger, K.; Kienzl, E.; Rumpelmair, G.; Riederer, P.; Stachelberger, H.; Ben-Shachar, D.; Youdim, M. B. H. Iron-melanin complex in substantia nigra of parkinsonian brains: an x-ray microanalysis. J. Neurochem. 59: 1168-1171; 1992.
45. Oakley, A. E.; Collingwood, J. F.; Dobson, J.; Love, G.; Perrott, H. R.; Edwardson, J. A.; Elstner, M.; Morris, C. M. Individual dopaminergic neurons show raised iron levels in Parkinson disease. Neurology 68: 1820-1825; 2007. (Pubitemid 46791395)
46. Dexter, D. T.; Carayon, A.; Javoy-Agid, F.; Agid, Y.; Wells, F. R.; Daniel, S. E.; Lees, A. J.; Jenner, P.; Marsden, C. D. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 114(Pt 4): 1953-1975; 1991.
47. Gerlach, M.; Ben-Shachar, D.; Riederer, P.; Youdim, M. B. Altered brain metabolism of iron as a cause of neurodegenerative diseases? J. Neurochem. 63: 793-807; 1994. (Pubitemid 24266591)
48. Sofic, E.; Riederer, P.; Heinsen, H.; Beckmann, H.; Reynolds, G. P.; Heben-streit, G.; Youdim, M. B. H. Increased iron(III) and total iron content in post mortem substantia nigra of parkinsonian brain. J. Neural Transm. 74: 199-205; 1988.
49. Sian-Hulsmann, J.; Mandel, S.; Youdim, M. B.; Riederer, P. The relevance of iron in the pathogenesis of Parkinson's disease. J. Neurochem. 118: 939-957; 2011.
50. Gerlach, M.; Double, K. L.; Youdim, M. B. H.; Riederer, P. Strategies for the protection of dopaminergic neurons against neurotoxicity. Neurotox. Res. 2: 99-114; 2000.
51. Youdim, M. B.; Stephenson, G.; Ben Shachar, D. Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chela-tors: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28. Ann. N. Y. Acad. Sci 1012: 306-325; 2004. (Pubitemid 38453534)
52. Zhu, W.; Li, X.; Xie, W.; Luo, F.; Kaur, D.; Andersen, J. K.; Jankovic, J.; Le, W. Genetic iron chelation protects against proteasome inhibition-induced dopamine neuron degeneration. Neurobiol. Dis. 37: 307-313; 2010.
53. Mastroberardino, P. G.; Hoffman, E. K.; Horowitz, M. P.; Betarbet, R.; Taylor, G.; Cheng, D.; Na, H. M.; Gutekunst, C. A.; Gearing, M.; Trojanowski, J. Q.; Anderson, M.; Chu, C. T.; Peng, J.; Greenamyre, J. T. A novel transferrin/TfR2-mediated mitochondrial iron transport system is disrupted in Parkinson's disease. Neurobiol. Dis. 34: 417-431; 2009.
54. Bartzokis, G.; Beckson, M.; Hance, D. B.; Marx, P.; Foster, J. A.; Marder, S. R. MR evaluation of age-related increase of brain iron in young adult and older normal males. Magn. Reson. Imaging 15: 29-35; 1997. (Pubitemid 27143746)
55. Crichton, R. R.; Pierre, J. L. Old iron, young copper: from Mars to Venus. Biometals 14: 99-112; 2001. (Pubitemid 32656569)
56. Brun, A.; Englund, E. A white matter disorder in dementia of the Alzheimer type: a pathoanatomical study. Ann. Neurol. 19: 253-262; 1986. (Pubitemid 16111074)
57. Snowdon, D. A. Healthy aging and dementia: findings from the Nun Study. Ann. Intern. Med. 139: 450-454; 2003. (Pubitemid 38120875)
58. Faucheux, B. A.; Bonnet, A. M.; Agid, Y.; Hirsch, E. C. Blood vessels change in the mesencephalon of patients with Parkinson's disease. Lancet 353: 981-982; 1999. (Pubitemid 29132612)
59. Bartzokis, G.; Mintz, J.; Sultzer, D.; Marx, P.; Herzberg, J. S.; Phelan, C. K.; Marder, S. R. In vivo MR evaluation of age-related increases in brain iron. Am. J. Neuroradiol 15: 1129-1138; 1994. (Pubitemid 24184373)
60. Youdim, M. B. Brain iron deficiency and excess: cognitive impairment and neurodegeneration with involvement of striatum and hippocampus. Neu-rotox. Res 14: 45-56; 2008.
61. Benkovic, S. A.; Connor, J. R. Ferritin, transferrin, and iron in selected regions of the adult and aged rat brain. J. Comp. Neurol. 338: 97-113; 1993. (Pubitemid 23337259)
62. Connor, J. R.; Menzies, S. L.; Burdo, J. R.; Boyer, P. J. Iron and iron management proteins in neurobiology. Pediatr. Neurol. 25: 118-129; 2001. (Pubitemid 32830161)
63. Connor, J. R.; Menzies St S. L.; Martin, S. M.; Mufson, E. J. A histochemical study of iron, transferrin, and ferritin in Alzheimer's diseased brains. J. Neurosci. Res. 31: 75-83; 1992.
64. Connor, J. R.; Snyder, B. S.; Arosio, P.; Loeffler, D. A.; LeWitt, P. A quantitative analysis of isoferritins in select regions of aged, parkinsonian, and Alzheimer's diseased brains. J. Neurochem. 65: 717-724; 1995.
65. Bartzokis, G.; Cummings, J.; Perlman, S.; Hance, D. B.; Mintz, J. Increased basal ganglia iron levels in Huntington disease. Arch. Neurol. 56: 569-574; 1999. (Pubitemid 29218152)
66. Snyder, A. M.; Connor, J. R. Iron, the substantia nigra and related neurological disorders. Biochim. Biophys. Acta 606-614: 2009; 1790.
67. Altamura, S.; Muckenthaler, M. U. Iron toxicity in diseases of aging: Alzheimer's disease, Parkinson's disease and atherosclerosis. J. Alzheimers Dis. 16: 879-895; 2009.
68. Riederer, P.; Dirr, A.; Goetz, M.; Sofic, E.; Jellinger, K.; Youdim, M. B. H. Distribution of iron in different brain regions and subcellular compartments in Parkinson's disease. Ann. Neurol. 32(Suppl):S101-104; 1992.
69. Vymazal, J.; Righini, A.; Brooks, R. A.; Canesi, M.; Mariani, C.; Leonardi, M.; Pezzoli, G. T1 and T2 in the brain of healthy subjects, patients with Parkinson disease, and patients with multiple system atrophy: relation to iron content. Radiology 211: 489-495; 1999. (Pubitemid 29206821)
70. Zhang, W.; Phillips, K.; Wielgus, A. R.; Liu, J.; Albertini, A.; Zucca, F. A.; Faust, R.; Qian, S. Y.; Miller, D. S.; Chignell, C. F.; Wilson, B.; Jackson-Lewis, V.; Przedborski, S.; Joset, D.; Loike, J.; Hong, J. S.; Sulzer, D.; Zecca, L. Neuromelanin activates microglia and induces degeneration of dopaminer-gic neurons: implications for progression of Parkinson's disease. Neurotox. Res. 19: 63-72; 2011.
71. Jellinger, K.; Paulus, W.; Grundke-Iqbal, I.; Riederer, P.; Youdim, M. B. H. Brain iron and ferritin in Parkinson's and Alzheimer's diseases. J. Neural Transm. 2: 327-340; 1990.
72. Zecca, L.; Gallorini, M.; Schunemann, V.; Trautwein, A. X.; Gerlach, M.; Riederer, P.; Vezzoni, P.; Tampellini, D. Iron, neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages: consequences for iron storage and neurodegenerative processes. J. Neuro-chem. 76: 1766-1773; 2001. (Pubitemid 32221116)
73. Koziorowski, D.; Friedman, A.; Arosio, P.; Santambrogio, P.; Dziewulska, D. ELISA reveals a difference in the structure of substantia nigra ferritin in Parkinson's disease and incidental Lewy body compared to control. Parkin-sonism Relat. Disord 13: 214-218; 2007. (Pubitemid 46603035)
74. Curtis, A. R.; Fey, C.; Morris, C. M.; Bindoff, L. A.; Ince, P. G.; Chinnery, P. F.; Coulthard, A.; Jackson, M. J.; Jackson, A. P.; McHale, D. P.; Hay, D.; Barker, W. A.; Markham, A. F.; Bates, D.; Curtis, A.; Burn, J. Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease. Nat. Genet. 28: 350-354; 2001. (Pubitemid 32702424)
75. Moos, T.; Morgan, E. H. The metabolism of neuronal iron and its pathogenic role in neurological disease: review. Ann. N. Y. Acad. Sci. 1012: 14-26; 2004. (Pubitemid 38453512)
76. Salazar, J.; Mena, N.; Hunot, S.; Prigent, A.; Alvarez-Fischer, D.; Arredondo, M.; Duyckaerts, C.; Sazdovitch, V.; Zhao, L.; Garrick, L. M.; Nunez, M. T.; Garrick, M. D.; Raisman-Vozari, R.; Hirsch, E. C. Divalent metal transporter 1 (DMT1) contributes to neurodegeneration in animal models of Parkinson's disease. Proc. Natl. Acad. Sci. USA 105: 18578-18583; 2008.
77. Jiang, H.; Song, N.; Xu, H.; Zhang, S.; Wang, J.; Xie, J. Up-regulation of divalent metal transporter 1 in 6-hydroxydopamine intoxication is IRE/IRP dependent. Cell Res. 20: 345-356; 2010.
78. Morris, C. M.; Candy, J. M.; Omar, S.; Bloxham, C. A.; Edwardson, J. A. Transferrin receptors in the parkinsonian midbrain. Neuropathol. Appl. Neurobiol. 20: 468-472; 1994. (Pubitemid 24326469)
79. Faucheux, B. A.; Hauw, J. J.; Agid, Y.; Hirsch, E. C. The density of [125I]-transferrin binding sites on perikarya of melanized neurons of the sub-stantia nigra is decreased in Parkinson's disease. Brain Res 749: 170-174; 1997. (Pubitemid 27096473)
80. Li, X. P.; Xie, W. J.; Zhang, Z.; Kansara, S.; Jankovic, J.; Le, W. D. A mechanistic study of proteasome inhibition-induced iron misregulation in dopamine neuron degeneration. Neurosignals 20: 223-236; 2012.
81. Zhu, W.; Xie, W.; Pan, T.; Xu, P.; Fridkin, M.; Zheng, H.; Jankovic, J.; Youdim, M. B.; Le, W. Prevention and restoration of lactacystin-induced nigrostriatal dopamine neuron degeneration by novel brain-permeable iron chelators. FASEB J 21: 3835-3844; 2007. (Pubitemid 350232341)
82. Zhang, J.; Zhang, Y.; Wang, J.; Cai, P.; Luo, C.; Qian, Z.; Dai, Y.; Feng, H. Characterizing iron deposition in Parkinson's disease using susceptibility-weighted imaging: an in vivo MR study. Brain Res. 1330: 124-130; 2010.
83. Martin, W. R. Quantitative estimation of regional brain iron with magnetic resonance imaging. Parkinsonism Relat. Disord 15(Suppl. 3):S215-218; 2009.
84. Bartzokis, G.; Cummings, J. L.; Markham, C. H.; Marmarelis, P. Z.; Treciokas, L. J.; Tishler, T. A.; Marder, S. R.; Mintz, J. MRI evaluation of brain iron in earlier- and later-onset Parkinson's disease and normal subjects. Magn. Reson. Imaging 17: 213-222; 1999. (Pubitemid 29053180)
85. LaVaute, T.; Smith, S.; Cooperman, S.; Iwai, K.; Land, W.; Meyron-Holtz, E.; Drake, S. K.; Miller, G.; Abu-Asab, M.; Tsokos, M.; Switzer 3rd R.; Grinberg, A.; Love, P.; Tresser, N.; Rouault, T. A. Targeted deletion of the gene encoding iron regulatory protein-2 causes misregulation of iron metabolism and neurodegenerative disease in mice. Nat. Genet. 27: 209-214; 2001. (Pubitemid 32157451)
86. Hunter, R. L.; Liu, M.; Choi, D. Y.; Cass, W. A.; Bing, G. Inflammation and age-related iron accumulation in F344 rats. Curr. Aging Sci 1: 112-121; 2008.
87. Sengstock, G. J.; Olanow, C. W.; Menzies, R. A.; Dunn, A. J.; Arendash, G. W. Infusion of iron into the rat substantia nigra: nigral pathology and dose-dependent loss of striatal dopaminergic markers. J. Neurosci. Res. 35: 67-82; 1993. (Pubitemid 23143633)
88. Pinero, D. J.; Hu, J.; Connor, J. R. Alterations in the interaction between iron regulatory proteins and their iron responsive element in normal and Alzheimer's diseased brains. Cell. Mol. Biol. (Noisy-Le-Grand) 46: 761-776; 2000.
89. Mounsey, R. B.; Teismann, P. Chelators in the treatment of iron accumulation in Parkinson's disease. Int. J. Cell Biol. : 983245; 2012. 2012.
90. Schulz, J. B.; Matthews, R. T.; Muqit, M. M.; Browne, S. E.; Beal, M. F. Inhibition of neuronal nitric oxide synthase by 7-nitroindazole protects against MPTP-induced neurotoxicity in mice. J. Neurochem. 64: 936-939; 1995.
91. Jellinger, K.; Linert, L.; Kienzl, E.; Herlinger, E.; Youdim, M. B. H. Chemical evidence for 6-hydroxydopamine to be an endogenous toxic factor in the pathogenesis of Parkinson's disease. J. Neural Transm. Suppl. 46: 297-314; 1995. (Pubitemid 26043238)
92. Linert, W.; Herlinger, E.; Jameson, R. F.; Kienzl, E.; Jellinger, K.; Youdim, M. B. H. Dopamine, 6-hydroxydopamine, iron, and dioxygen - their mutual interactions and possible implication in the development of Parkinson's disease. Biochim. Biophys. Acta 1316: 160-168; 1996. (Pubitemid 26273700)
93. Drechsel, D. A.; Patel, M. Role of reactive oxygen species in the neurotoxi-city of environmental agents implicated in Parkinson's disease. Free Radic. Biol. Med 44: 1873-1886; 2008.
94. Lan, J.; Jiang, D. H. Excessive iron accumulation in the brain: a possible potential risk of neurodegeneration in Parkinson's disease. J. Neural Transm 104: 649-660; 1997. (Pubitemid 27474679)
95. Han, J.; Cheng, F. C.; Yang, Z.; Dryhurst, G. Inhibitors of mitochondrial respiration, iron(II), and hydroxyl radical evoke release and extracellular hydrolysis of glutathione in rat striatum and substantia nigra: potential implications to Parkinson's disease. J. Neurochem 73: 1683-1695; 1999. (Pubitemid 29440172)
96. Bharath, S.; Hsu, M.; Kaur, D.; Rajagopalan, S.; Andersen, J. K. Glutathione, iron and Parkinson's disease. Biochem. Pharmacol. 64: 1037-1048; 2002.
97. Youdim, M. B. H.; Ben-Shachar, D.; Riederer, P. The role of monoamine oxidase, iron-melanin interaction, and intracellular calcium in Parkinson's disease. J. Neural Transm. Suppl. 32: 239-248; 1990.
98. Jenner, P. Oxidative stress as a cause of Parkinson's disease. Acta Neurol. Scand. Suppl. 136: 6-15; 1991.
99. Youdim, M. B. H. A review of the mechanisms and role of monoamine oxidase inhibitors in Parkinson's disease. Neurology 63:S32-35 ; 2004. (Pubitemid 39346709)
100. Uversky, V. N.; Li, J.; Fink, A. L. Metal-triggered structural transformations, aggregation, and fibrillation of human a-synuclein: a possible molecular link between Parkinson's disease and heavy metal exposure. J. Biol. Chem. 276: 44284-44296; 2001.
101. Gotz, M. E.; Double, K.; Gerlach, M.; Youdim, M. B. H.; Riederer, P. The relevance of iron in the pathogenesis of Parkinson's disease. Ann. N. Y. Acad. Sci. 1012: 193-208; 2004. (Pubitemid 38455479)
102. Castellani, R. J.; Siedlak, S. L.; Perry, G.; Smith, M. A. Sequestration of iron by Lewy bodies in Parkinson's disease. Acta Neuropathol. 100: 111-114; 2000. (Pubitemid 30456131)
103. Napolitano, M.; Centonze, D.; Calce, A.; Picconi, B.; Spiezia, S.; Gulino, A.; Bernardi, G.; Calabresi, P. Experimental parkinsonism modulates multiple genes involved in the transduction of dopaminergic signals in the striatum. Neurobiol. Dis. 10: 387-395; 2002. (Pubitemid 35217590)
104. Maharaj, H.; Sukhdev Maharaj, D.; Scheepers, M.; Mokokong, R.; Daya, S. l-DOPA administration enhances 6-hydroxydopamine generation. Brain Res. 1063: 180-186; 2005. (Pubitemid 41741029)
105. Braak, H.; Del Tredici, K. Poor and protracted myelination as a contributory factor to neurodegenerative disorders. Neurobiol. Aging 25: 19-23; 2004. (Pubitemid 37522187)
106. Kumar, M. J.; Andersen, J. K. Perspectives on MAO-B in aging and neurological disease: where do we go from here? Mol. Neurobiol 30: 77-89; 2004. (Pubitemid 41271221)
107. Shemyakov, S. E. Monoamine oxidase activity, lipid peroxidation, and morphological changes in human hypothalamus during aging. Bull. Exp. Biol. Med. 131: 586-588; 2001. (Pubitemid 34051354)
108. Fowler, J. S.; Logan, J.; Wang, G. J.; Volkow, N. D.; Zhu, W.; Franceschi, D.; Pappas, N.; Ferrieri, R.; Shea, C.; Garza, V.; Xu, Y.; MacGregor, R. R.; Schlyer, D.; Gatley, S. J.; Ding, Y. S.; Alexoff, D. PET imaging of monoamine oxidase B in peripheral organs in humans. J. Nucl. Med. 43: 1331-1338; 2002.
109. Cohen, G. Oxidative stress, mitochondrial respiration, and Parkinson's disease. Ann. N. Y. Acad. Sci. 899: 112-120; 2000. (Pubitemid 30352780)
110. Fowler, C. J.; Wiberg, A.; Oreland, L.; Marcusson, J.; Winblad, B. The effect of age on the activity and molecular properties of human brain monoamine oxidase. J. Neural Transm. 49: 1-20; 1980. (Pubitemid 10030548)
111. Bisaglia, M.; Tessari, I.; Mammi, S.; Bubacco, L. Interaction between alpha-synuclein and metal ions, still looking for a role in the pathogenesis of Parkinson's disease. Neuromol. Med 11: 239-251; 2009.
112. Galvin, J. E.; Giasson, B.; Hurtig, H. I.; Lee, V. M.; Trojanowski, J. Q. Neurodegeneration with brain iron accumulation, type 1 is characterized by alpha-, beta-, and gamma-synuclein neuropathology. Am. J. Pathol. 157: 361-368; 2000. (Pubitemid 30626903)
113. Jellinger, K. A. Neuropathological spectrum of synucleinopathies. Mov. Disord 18(Suppl. 6):S2-12; 2003.
114. Tofaris, G. K.; Revesz, T.; Jacques, T. S.; Papacostas, S.; Chataway, J. Adult-onset neurodegeneration with brain iron accumulation and cortical alpha-synuclein and tau pathology: a distinct clinicopathological entity. Arch. Neurol. 64: 280-282; 2007.
115. Sangchot, P.; Sharma, S.; Chetsawang, B.; Porter, J.; Govitrapong, P.; Ebadi, M. Deferoxamine attenuates iron-induced oxidative stress and prevents mitochondrial aggregation and a-synuclein translocation in SK-N-SH cells in culture. Dev. Neurosci. 24: 143-153; 2002. (Pubitemid 36151444)
116. Li, W.; Jiang, H.; Song, N.; Xie, J. Oxidative stress partially contributes to iron-induced alpha-synuclein aggregation in SK-N-SH cells. Neurotox. Res. 19: 435-442; 2010.
117. Li, W. J.; Jiang, H.; Song, N.; Xie, J. X. Dose- and time-dependent alpha-synuclein aggregation induced by ferric iron in SK-N-SH cells. Neurosci. Bull 26: 205-210; 2010.
118. He, Q.; Song, N.; Xu, H.; Wang, R.; Xie, J.; Jiang, H. Alpha-synuclein aggregation is involved in the toxicity induced by ferric iron to SK-N-SH neuroblastoma cells. J. Neural Transm. 118: 397-406; 2011.
119. Martin, F. L.; Williamson, S. J.; Paleologou, K. E.; Hewitt, R.; El-Agnaf, O. M.; Allsop, D. Fe(II)-induced DNA damage in alpha-synuclein- transfected human dopaminergic BE(2)-M17 neuroblastoma cells: detection by the comet assay. J. Neurochem. 87: 620-630; 2003. (Pubitemid 37310628)
120. Chew, K. C.; Ang, E. T.; Tai, Y. K.; Tsang, F.; Lo, S. Q.; Ong, E.; Ong, W. Y.; Shen, H. M.; Lim, K. L.; Dawson, V. L.; Dawson, T. M.; Soong, T. W. Enhanced autophagy from chronic toxicity of iron and mutant A53T alpha-synuclein: implications for neuronal cell death in Parkinson disease. J. Biol. Chem. 286: 33380-33389; 2010.
121. Davies, P.; Moualla, D.; Brown, D. R. Alpha-synuclein is a cellular ferrir-eductase. PLoS One 6:e15814; 2011.
122. Friedlich, A. L.; Tanzi, R. E.; Rogers, J. T. The 50 -untranslated region of Parkinson's disease alpha-synuclein messengerRNA contains a predicted iron responsive element. Mol. Psychiatry 12: 222-223; 2007. (Pubitemid 46328508)
123. Binolfi, A.; Rasia, R. M.; Bertoncini, C. W.; Ceolin, M.; Zweckstetter, M.; Griesinger, C.; Jovin, T. M.; Fernandez, C. O. Interaction of alpha-synuclein with divalent metal ions reveals key differences: a link between structure, binding specificity and fibrillation enhancement. J. Am. Chem. Soc. 128: 9893-9901; 2006. (Pubitemid 44147975)
124. Kostka, M.; Hogen, T.; Danzer, K. M.; Levin, J.; Habeck, M.; Wirth, A.; Wagner, R.; Glabe, C. G.; Finger, S.; Heinzelmann, U.; Garidel, P.; Duan, W.; Ross, C. A.; Kretzschmar, H.; Giese, A. Single particle characterization of iron-induced pore-forming alpha-synuclein oligomers. J. Biol. Chem. 283: 10992-11003; 2008.
125. Van der Schyf, C. J.; Gal, S.; Geldenhuys, W. J.; Youdim, M. B. Multifunctional neuroprotective drugs targeting monoamine oxidase inhibition, iron chelation, adenosine receptors, and cholinergic and glutamatergic action for neurodegenerative diseases. Expert Opin. Invest. Drugs 15: 873-886; 2006. (Pubitemid 44177841)
126. Mandel, S. A.; Amit, T.; Kalfon, L.; Reznichenko, L.; Weinreb, O.; Youdim, M. B. Cell signaling pathways and iron chelation in the neurorestorative activity of green tea polyphenols: special reference to epigallocatechin gallate (EGCG). J. Alzheimers Dis. 15: 211-222; 2008.
127. Bolognin, S.; Drago, D.; Messori, L.; Zatta, P. Chelation therapy for neuro-degenerative diseases. Med. Res. Rev. 29: 547-570; 2009.
128. Weinreb, O.; Mandel, S.; Bar-Am, O.; Amit, T. Iron-chelating backbone coupled with monoamine oxidase inhibitory moiety as novel pluripotential therapeutic agents for Alzheimer's disease: a tribute to Moussa Youdim. J. Neural Transm 118: 479-492; 2011.
129. Flaten, T. P.; Aaseth, J.; Andersen, O.; Kontoghiorghes, G. J. Iron mobilization using chelation and phlebotomy. J. Trace Elem. Med. Biol. 26: 127-130; 2012.
130. Keberle, H. The biochemistry of desferrioxamine and its relation to iron metabolism. Ann. N. Y. Acad. Sci. 119: 758-768; 1964.
131. Ben-Shachar, D.; Eshel, G.; Riederer, P.; Youdim, M. B. H. Role of iron and iron chelation in dopaminergic-induced neurodegeneration: implication for Parkinson's disease. Ann. Neurol. 32(Suppl):S105-110; 1992.
132. Ben-Shachar, D.; Finberg, J. P.; Youdim, M. B. H. Effect of iron chelators on dopamine D2 receptors. J. Neurochem. 45: 999-1005; 1985. (Pubitemid 16258140)
133. Ben-Shachar, D.; Eshel, G.; Finberg, J. P.; Youdim, M. B. The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons. J. Neurochem. 56: 1441-1444; 1991. (Pubitemid 21902069)
134. Lan, J.; Jiang, D. H. Desferrioxamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice. J. Neural Transm. (Budapest) 104: 469-481; 1997. (Pubitemid 27379903)
135. Molina-Holgado, F.; Gaeta, A.; Francis, P. T.; Williams, R. J.; Hider, R. C. Neuroprotective actions of deferiprone in cultured cortical neurones and SHSY-5Y cells. J. Neurochem. 105: 2466-2476; 2008. (Pubitemid 351782272)
136. Dexter, D. T.; Statton, S. A.; Whitmore, C; Freinbichler, W.; Weinberger, P.; Tipton, K. F.; Della Corte, L.; Ward, R.J.; Crichton, R. R. Clinically available iron chelators induce neuroprotection in the 6-OHDA model of Parkinson's disease after peripheral administration. J. Neural Transm. 118: 223-231; 2011.
137. Kaur, D.; Yantiri, F.; Rajagopalan, S.; Kumar, J.; Mo, J. Q.; Boonplueang, R.; Viswanath, V.; Jacobs, R.; Yang, L.; Beal, M. F.; DiMonte, D.; Volitaskis, I.; Ellerby, L.; Cherny, R. A.; Bush, A. I.; Andersen, J. K. Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron 37: 899-909; 2003. (Pubitemid 36398297)
138. Cherny, R.; George, J.; Critch, N.; Cortes, M.; Liu, X.; Nurjono, M.; Laughton, K.; Volitakis, I.; Masters, C; Parsons, J.; Gautier, E.; Barnham, K.; Bush, A.; Finkelstein, D. PBT434: a novel 8-hydroxyquinazolin-4 (3H)-one provides robust neuroprotection in transgenic and toxin animal models of PD associated with reduced nigral alpha-synuclein and elevated PARK7 (DJ-1). Neurodegener. Dis. 8(Suppl. 1); 2011.
139. Checkoway, H.; Powers, K.; Smith-Weller, T.; Franklin, G. M.; Longstreth Jr W. T.; Swanson, P. D. Parkinson's disease risks associated with cigarette smoking, alcohol consumption, and caffeine intake. Am. J. Epidemiol. 155: 732-738; 2002. (Pubitemid 34297653)
140. Kuriyama, S.; Hozawa, A.; Ohmori, K.; Shimazu, T.; Matsui, T.; Ebihara, S.; Awata, S.; Nagatomi, R.; Arai, H.; Tsuji, I. Green tea consumption and cognitive function: a cross-sectional study from the Tsurugaya Project 1. Am. J. Clin. Nutr. 83: 355-361; 2006. (Pubitemid 44713198)
141. Ng, T. P.; Feng, L.; Niti, M.; Kua, E. H.; Yap, K. B. Tea consumption and cognitive impairment and decline in older Chinese adults. Am. J. Clin. Nutr. 88: 224-231; 2008. (Pubitemid 351988703)
142. Tan, L. C; Koh, W. P.; Yuan, J. M.; Wang, R.; Au, W. L.; Tan, J. H.; Tan, E. K.; Yu, M. C. Differential effects of black versus green tea on risk of Parkinson's disease in the Singapore Chinese Health Study. Am. J. Epidemiol. 167: 553-560; 2008. (Pubitemid 351323310)
143. Levites, Y.; Weinreb, O.; Maor, G.; Youdim, M. B. H.; Mandel, S. Green tea polyphenol (-) -epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-induced dopaminergic neurodegeneration. J. Neurochem. 78: 1073-1082; 2001. (Pubitemid 32823156)
144. Kim, J. S.; Kim, J. M.; O, J. J.; Jeon, B. S. Inhibition of inducible nitric oxide synthase expression and cell death by (-) -epigallocatechin-3- gallate, a green tea catechin, in the 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine mouse model of Parkinson's disease. J. Clin. Neurosci 17: 1165-1168; 2012.
145. Nie, G.; Jin, C; Cao, Y.; Shen, S.; Zhao, B. Distinct effects of tea catechins on 6-hydroxydopamine-induced apoptosis in PC12 cells. Arch. Biochem. Bio-phys. 397: 84-90; 2002. (Pubitemid 34848252)
146. Levites, Y.; Amit, T.; Youdim, M. B.; Mandel, S. Involvement of protein kinase C activation and cell survival/cell cycle genes in green tea polyphenol (-) -epigallocatechin 3-gallate neuroprotective action. J. Biol. Chem 277: 30574-30580; 2002. (Pubitemid 34970751)
147. Levites, Y.; Youdim, M. B. H.; Maor, G.; Mandel, S. Attenuation of 6-hydroxydopamine (6-OHDA)-induced nuclear factor-kappaB (NF-kappaB) activation and cell death by tea extracts in neuronal cultures. Biochem. Pharmacol 63: 21-29; 2002. (Pubitemid 34075289)
148. Wang, L.; Xu, S.; Xu, X.; Chan, P. (-) -Epigallocatechin-3-gallate
149. Richardson, D. R. Novel chelators for central nervous system disorders that involve alterations in the metabolism of iron and other metal ions. Ann. N. Y. Acad. Sci 1012: 326-341; 2004. (Pubitemid 38453535)
150. Bareggi, S. R.; Cornelli, U. Clioquinol: review of its mechanisms of action and clinical uses in neurodegenerative disorders. CNS Neurosci. Ther. 18: 41-46; 2012.
151. Hidalgo, C; Carrasco, M. A.; Munoz, P.; Nunez, M. T. A role for reactive oxygen/nitrogen species and iron on neuronal synaptic plasticity. Antioxid. Redox Signaling 9: 245-255; 2007. (Pubitemid 46105423)
152. Hegde, M. L; Bharathi, P.; Suram, A.; Venugopal, C; Jagannathan, R.; Poddar, P.; Srinivas, P.; Sambamurti, K.; Rao, K. J.; Scancar, J.; Messori, L.; Zecca, L.; Zatta, P. Challenges associated with metal chelation therapy in Alzheimer's disease. J. Alzheimers Dis. 17: 457-468; 2009.
153. Zheng, H.; Weiner, L. M.; Bar-Am, O.; Epsztejn, S.; Cabantchik, Z. I.; Warshawsky, A.; Youdim, M. B.; Fridkin, M. Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases. Bioorg. Med. Chem. 13: 773-783; 2005. (Pubitemid 40093620)
154. Ben-Shachar, D.; Kahana, N.; Kampel, V.; Warshawsky, A.; Youdim, M. B. H. Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lesion in rats. Neuropharmacology 46: 254-263; 2004. (Pubitemid 37532833)
155. Bandyopadhyay, S.; Huang, X.; Cho, H.; Greig, N. H.; Youdim, M. B.; Rogers, J. T. Metal specificity of an iron-responsive element in Alzheimer's APP mRNA 5'untranslated region, tolerance of SH-SY5Y and H4 neural cells to desferoxamine, clioquinol, VK-28, and a piperazine chelator. J. Neural Transm. Suppl. 71: 237-247; 2006. (Pubitemid 351412125)
156. Youdim, M. B.; Fridkin, M.; Zheng, H. Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases. J. Neural Transm 111: 1455-1471; 2004. (Pubitemid 39468399)
157. Zheng, H.; Gal, S.; Weiner, L. M.; Bar-Am, O.; Warshawsky, A.; Fridkin, M.; Youdim, M. B. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition. J. Neurochem. 95: 68-78; 2005. (Pubitemid 41384426)
158. Zheng, H.; Youdim, M. B.; Weiner, L. M.; Fridkin, M. Novel potential neuroprotective agents with both iron chelating and amino acid-based derivatives targeting central nervous system neurons. Biochem. Pharmacol. 70: 1642-1652; 2005. (Pubitemid 41540357)
159. Gal, S.; Fridkin, M.; Amit, T.; Zheng, H.; Youdim, M. B. M30, a novel multifunctional neuroprotective drug with potent iron chelating and brain selective monoamine oxidase-ab inhibitory activity for Parkinson's disease. J. Neural Transm. Suppl. 70: 447-456; 2006. (Pubitemid 44622237)
160. Gal, S.; Zheng, H.; Fridkin, M.; Youdim, M. B. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion. J. Neurochem 95: 79-88; 2005. (Pubitemid 41384427)
161. Gal, S.; Abassi, Z. A.; Youdim, M. B. Limited potentiation of blood pressure in response to oral tyramine by the anti-Parkinson brain selective multifunctional monoamine oxidase-AB inhibitor, M30. Neurotox. Res 18: 143-150; 2009.
162. Tian, B.; Sun, Z.; Xu, Z.; Hua, Y. Chemiluminescence analysis of the prooxidant and antioxidant effects of epigallocatechin-3-gallate. Asia Pac. J. Clin. Nutr. 16(Suppl. 1): 153-157; 2007. (Pubitemid 46524592)
163. Zhang, B.; Tanaka, J.; Yang, L.; Yang, L.; Sakanaka, M.; Hata, R.; Maeda, N.; Mitsuda, N. Protective effect of vitamin E against focal brain ischemia and neuronal death through induction of target genes of hypoxia-inducible factor-1. Neuroscience 126: 433-440; 2004. (Pubitemid 38780819)
164. Higdon, J. V.; Frei, B. Tea catechins and polyphenols: health effects, metabolism, and antioxidant functions. Crit. Rev. Food Sci. Nutr. 43: 89-143; 2003. (Pubitemid 38552312)
165. Perron, N. R.; Brumaghim, J. L A review of the antioxidant mechanisms of polyphenol compounds related to iron binding. Cell Biochem. Biophys. 53: 75-100; 2009.
166. Weinreb, O.; Amit, T.; Mandel, S.; Youdim, M. B. Neuroprotective molecular mechanisms of (-) -epigallocatechin-3-gallate: a reflective outcome of its antioxidant, iron chelating and neuritogenic properties. Genes Nutr 4: 283-296; 2009.
167. Nanjo, F.; Goto, K.; Seto, R.; Suzuki, M.; Sakai, M.; Hara, Y. Scavenging effects of tea catechins and their derivatives on 1,1-diphenyl-2-picrylhydrazyl radical. Free Radic. Biol. Med. 21: 895-902; 1996. (Pubitemid 26365284)
168. Kumamoto, M.; Sonda, T.; Nagayama, K.; Tabata, M. Effects of pH and metal ions on antioxidative activities of catechins. Biosci. Biotechnol. Biochem. 65: 126-132; 2001. (Pubitemid 33617450)
169. Perron, N. R.; Hodges, J. N.; Jenkins, M.; Brumaghim, J. L. Predicting how polyphenol antioxidants prevent DNA damage by binding to iron. Inorg. Chem. 47: 6153-6161; 2008.
170. Lee, S. R.; Im, K. J.; Suh, S. I.; Jung, J. G. Protective effect of green tea polyphenol (-) -epigallocatechin gallate and other antioxidants on lipid peroxidation in gerbil brain homogenates. Phytother. Res. 17: 206-209; 2003.
171. Mazzio, E. A.; Harris, N.; Soliman, K. F. Food constituents attenuate monoamine oxidase activity and peroxide levels in C6 astrocyte cells. Planta Med. 64: 603-606; 1998. (Pubitemid 28481470)
172. Lin, S. M.; Wang, S. W.; Ho, S. C; Tang, Y. L Protective effect of green tea (-) -epigallocatechin-3-gallate against the monoamine oxidase B enzyme activity increase in adult rat brains. Nutrition 26: 1195-1200; 2010.
173. Avramovich-Tirosh, Y.; Amit, T.; Bar-Am, O.; Zheng, H.; Fridkin, M.; Youdim, M. B. Therapeutic targets and potential of the novel brain-permeable multifunctional iron chelator-monoamine oxidase inhibitor drug, M-30, for the treatment of Alzheimer's disease. J. Neurochem. 100: 490-502; 2007. (Pubitemid 46016026)
174. Avramovich-Tirosh, Y.; Reznichenko, L.; Mit, T.; Zheng, H.; Fridkin, M.; Weinreb, O.; Mandel, S.; Youdim, M. B. Neurorescue activity, APP regulation and amyloid-beta peptide reduction by novel multi-functional brain permeable iron-chelating antioxidants, M-30 and green tea polyphenol, EGCG. Curr. Alzheimer Res. 4: 403-411; 2007. (Pubitemid 47416633)
175. Kupershmidt, L; Weinreb, O.; Amit, T.; Mandel, S.; Carri, M. T.; Youdim, M. B. Neuroprotective and neuritogenic activities of novel multimodal iron-chelating drugs in motor-neuron-like NSC-34 cells and transgenic mouse model of amyotrophic lateral sclerosis. FASEB J 23: 3766-3779; 2009.
176. Kupershmidt, L.; Weinreb, O.; Amit, T.; Mandel, S.; Bar-Am, O.; Youdim, M. B. Novel molecular targets of the multi-functional brain-permeable iron chelating drug M30 in mouse brain. Neuroscience 189: 345-358; 2011.
177. Carrillo, M. C; Minami, C; Kitani, K.; Maruyama, W.; Ohashi, K.; Yamamoto, T.; Naoi, M.; Kanai, S.; Youdim, M. B. H. Enhancing effect of rasagiline on superoxide dismutase and catalase activities in the dopaminergic system in the rat. Life Sci. 67: 577-585; 2000. (Pubitemid 30431547)
178. Kitani, K.; Minami, C; Maruyama, W.; Kanai, S.; Ivy, G. O.; Carrillo, M. C. Common properties for propargylamines of enhancing superoxide dismutase and catalase activities in the dopaminergic system in the rat: implications for the life prolonging effect of (-) deprenyl. J. Neural. Transm. Suppl. 60: 139-156; 2000. (Pubitemid 32037190)
179. Naoi, M.; Maruyama, W. Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson's disease. Expert Rev. Neurother 9: 1233-1250; 2009.
180. Wang, G. L.; Semenza, G. L. Purification and characterization of hypoxia-inducible factor 1. J. Biol. Chem. 270: 1230-1237; 1995.
181. Bergeron, M.; Yu, A. Y.; Solway, K. E.; Semenza, G. L.; Sharp, F. R. Induction of hypoxia-inducible factor-1 (HIF-1) and its target genes following focal ischaemia in rat brain. Eur. J. Neurosci. 11: 4159-4170; 1999. (Pubitemid 30009246)
182. Semenza, G. L. Hypoxia-inducible factor 1: oxygen homeostasis and disease pathophysiology. Trends Mol. Med. 7: 345-350; 2001. (Pubitemid 32735019)
183. Zaman, K.; Ryu, H.; Hall, D.; O'Donovan, K.; Lin, K. I.; Miller, M. P.; Marquis, J. C.; Baraban, J. M.; Semenza, G. L.; Ratan, R. R. Protection from oxidative stress-induced apoptosis in cortical neuronal cultures by iron chelators is associated with enhanced DNA binding of hypoxia-inducible factor-1 and ATF-1/CREB and increased expression of glycolytic enzymes, p21(waf1/cip1), and erythropoietin. J. Neurosci. 19: 9821-9830; 1999. (Pubitemid 30226655)
184. Mendel, G. A. Studies on iron absorption. I. The relationships between the rate of erythropoiesis, hypoxia and iron absorption. Blood 18: 727-736; 1961.
185. Hewitson, K. S.; Schofield, C. J. The HIF pathway as a therapeutic target. Drug Discovery Today 9: 704-711; 2004. (Pubitemid 39070283)
186. Siddiq, A.; Aminova, L. R.; Ratan, R. R. Prolyl 4-hydroxylase activity-responsive transcription factors: from hydroxylation to gene expression and neuroprotection. Front. Biosci. 13: 2875-2887; 2008. (Pubitemid 351589204)
187. Fandrey, J. Oxygen-dependent and tissue-specific regulation of erythropoietin gene expression. Am. J. Physiol. Regul. Integr. Comp. Physiol 286:R977-988; 2004. (Pubitemid 38661383)
188. Bruick, R. K. Oxygen sensing in the hypoxic response pathway: regulation of the hypoxia-inducible transcription factor. Genes Dev 17: 2614-2623; 2003. (Pubitemid 37363065)
189. Siddiq, A.; Aminova, L. R.; Ratan, R. R. Hypoxia inducible factor prolyl 4-hydroxylase enzymes: center stage in the battle against hypoxia, metabolic compromise and oxidative stress. Neurochem. Res. 32: 931-946; 2007. (Pubitemid 46481318)
190. Kaelin, W. G. Proline hydroxylation and gene expression. Annu. Rev. Biochem. 74: 115-128; 2005.
191. Piret, J. P.; Lecocq, C.; Toffoli, S.; Ninane, N.; Raes, M.; Michiels, C. Hypoxia and CoCl2 protect HepG2 cells against serum deprivation- and t-BHP-induced apoptosis: a possible anti-apoptotic role for HIF-1. Exp. Cell Res. 295: 340-349; 2004. (Pubitemid 38490490)
192. Bernhardt, W. M.; Warnecke, C.; Willam, C.; Tanaka, T.; Wiesener, M. S.; Eckardt, K. U. Organ protection by hypoxia and hypoxia-inducible factors. Methods Enzymol. 435: 221-245; 2007.
193. Schofield, C. J.; Ratcliffe, P. J. Oxygen sensing by HIF hydroxylases. Nat. Rev. Mol. Cell Biol. 5: 343-354; 2004. (Pubitemid 38579472)
194. Mole, D. R. Iron homeostasis and its interaction with prolyl hydroxylases. Antioxid. Redox Signaling 12: 445-458; 2010.
195. Hanauske-Abel, H. M. Prolyl 4-hydroxylase, a target enzyme for drug development: design of suppressive agents and the in vitro effects of inhibitors and proinhibitors. J. Hepatol. 13(Suppl. 3); 1991. S8-15; discussion S16.
196. Maxwell, P. H.; Wiesener, M. S.; Chang, G. W.; Clifford, S. C.; Vaux, E. C.; Cockman, M. E.; Wykoff, C. C.; Pugh, C. W.; Maher, E. R.; Ratcliffe, P. J. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399: 271-275; 1999. (Pubitemid 29246458)
197. Mastrogiannaki, M.; Matak, P.; Keith, B.; Simon, M. C.; Vaulont, S.; Peyssonnaux, C. HIF-2alpha, but not HIF-1alpha, promotes iron absorption in mice. J. Clin. Invest. 119: 1159-1166; 2009.
198. Sanchez, M.; Galy, B.; Muckenthaler, M. U.; Hentze, M. W. Iron-regulatory proteins limit hypoxia-inducible factor-2alpha expression in iron deficiency. Nat. Struct. Mol. Biol. 14: 420-426; 2007. (Pubitemid 46685876)
199. Zimmer, M.; Ebert, B. L.; Neil, C.; Brenner, K.; Papaioannou, I.; Melas, A.; Tolliday, N.; Lamb, J.; Pantopoulos, K.; Golub, T.; Iliopoulos, O. Small-molecule inhibitors of HIF-2a translation link its 50UTR iron-responsive element to oxygen sensing. Mol. Cell 32: 838-848; 2008.
200. Davis, M. R.; Shawron, K. M.; Rendina, E.; Peterson, S. K.; Lucas, E. A.; Smith, B. J.; Clarke, S. L. Hypoxia inducible factor-2 alpha is translationally repressed in response to dietary iron deficiency in Sprague-Dawley rats. J. Nutr. 141: 1590-1596; 2011.
201. Siddiq, A.; Aminova, L. R.; Troy, C. M.; Suh, K.; Messer, Z.; Semenza, G. L.; Ratan, R. R. Selective inhibition of hypoxia-inducible factor (HIF) prolyl-hydroxylase 1 mediates neuroprotection against normoxic oxidative death via HIF- and CREB-independent pathways. J. Neurosci. 29: 8828-8838; 2009.
202. Siddiq, A.; Ayoub, I. A.; Chavez, J. C.; Aminova, L.; Shah, S.; LaManna, J. C.; Patton, S. M.; Connor, J. R.; Cherny, R. A.; Volitakis, I.; Bush, A. I.; Langsetmo, I.; Seeley, T.; Gunzler, V.; Ratan, R. R. Hypoxia-inducible factor prolyl 4-hydroxylase inhibition: a target for neuroprotection in the central nervous system. J. Biol. Chem. 280: 41732-41743; 2005. (Pubitemid 41832236)
203. Avramovich-Tirosh, Y.; Bar-Am, O.; Amit, T.; Youdim, M. B.; Weinreb, O. Up-regulation of hypoxia-inducible factor (HIF)-1a and HIF-target genes in cortical neurons by the novel multifunctional iron chelator anti-Alzheimer drug, M30. Curr. Alzheimer Res 7: 300-306; 2010.
204. Lee, D. W.; Rajagopalan, S.; Siddiq, A.; Gwiazda, R.; Yang, L.; Beal, M. F.; Ratan, R. R.; Andersen, J. K. Inhibition of prolyl hydroxylase protects against MPTP-induced neurotoxicity: model for the potential involvement of the hypoxia-inducible factor pathway in Parkinson's disease. J. Biol. Chem. 284: 29065-29076; 2009.
205. Correia, S. C.; Moreira, P. I. Hypoxia-inducible factor 1: a new hope to counteract neurodegeneration? J. Neurochem. 112: 1-12; 2010.
206. Zhang, Z.; Yan, J.; Chang, Y.; ShiDu Yan, S.; Shi, H. Hypoxia inducible factor-1 as a target for neurodegenerative diseases. Curr. Med. Chem. 18: 4335-4343; 2011.
207. Witten, L.; Sager, T.; Thirstrup, K.; Johansen, J. L.; Larsen, D. B.; Montezinho, L. P.; Mork, A. HIF prolyl hydroxylase inhibition augments dopamine release in the rat brain in vivo. J. Neurosci. Res. 87: 1686-1694; 2009.
208. Johansen, J. L.; Sager, T. N.; Lotharius, J.; Witten, L.; Mork, A.; Egebjerg, J.; Thirstrup, K. HIF prolyl hydroxylase inhibition increases cell viability and potentiates dopamine release in dopaminergic cells. J. Neurochem. 115: 209-219; 2010.
209. Hamrick, S. E.; McQuillen, P. S.; Jiang, X.; Mu, D.; Madan, A.; Ferriero, D. M. A role for hypoxia-inducible factor-1alpha in desferoxamine neuroprotection. Neurosci. Lett. 379: 96-100; 2005.
210. Lee, P. J.; Jiang, B. H.; Chin, B. Y.; Iyer, N. V.; Alam, J.; Semenza, G. L; Choi, A. M. Hypoxia-inducible factor-1 mediates transcriptional activation of the heme oxygenase-1 gene in response to hypoxia. J. Biol. Chem. 272: 5375-5381; 1997. (Pubitemid 27102353)
211. Rolfs, A.; Kvietikova, I.; Gassmann, M.; Wenger, R. H. Oxygen-regulated transferrin expression is mediated by hypoxia-inducible factor-1. J. Biol. Chem. 272: 20055-20062; 1997. (Pubitemid 27340110)
212. Bianchi, L.; Tacchini, L.; Cairo, G. HIF-1-mediated activation of transferrin receptor gene transcription by iron chelation. Nucleic Acids Res 27: 4223-4227; 1999. (Pubitemid 29500256)
213. Hirsila, M.; Koivunen, P.; Xu, L.; Seeley, T.; Kivirikko, K. I.; Myllyharju, J. Effect of desferrioxamine and metals on the hydroxylases in the oxygen sensing pathway. FASEB J 19: 1308-1310; 2005. (Pubitemid 41113732)
214. Wu, Y.; Li, X.; Xie, W.; Jankovic, J.; Le, W.; Pan, T. Neuroprotection of deferoxamine on rotenone-induced injury via accumulation of HIF-1 alpha and induction of autophagy in SH-SY5Y cells. Neurochem. Int. 57: 198-205; 2010.
215. Zhou, Y. D.; Kim, Y. P.; Li, X. C; Baerson, S. R.; Agarwal, A. K.; Hodges, T. W.; Ferreira, D.; Nagle, D. G. Hypoxia-inducible factor-1 activation by (-) -epica-techin gallate: potential adverse effects of cancer chemoprevention with high-dose green tea extracts.J. Nat. Prod. 67: 2063-2069; 2004. (Pubitemid 40092556)
216. Thomas, R.; Kim, M. H. Epigallocatechin gallate inhibits HIF-1a degradation in prostate cancer cells. Biochem. Biophys. Res. Commun. 334: 543-548; 2005. (Pubitemid 40982400)
217. Febbraro, F.; Giorgi, M.; Caldarola, S.; Loreni, F.; Romero-Ramos, M. alpha-Synuclein expression is modulated at the translational level by iron. Neuroreport 23: 576-580; 2012.
218. Mandel, S.; Maor, G.; Youdim, M. B. Iron and alpha-synuclein in the substantia nigra of MPTP-treated mice: effect of neuroprotective drugs R-apomorphine and green tea polyphenol (-) -epigallocatechin-3-gallate. J. Mol. Neurosci 24: 401-416; 2004. (Pubitemid 41389377)
219. Caruana, M.; Hogen, T.; Levin, J.; Hillmer, A.; Giese, A.; Vassallo, N. Inhibition and disaggregation of alpha-synuclein oligomers by natural polyphenolic compounds. FEBS Lett. 585: 1113-1120; 2011.
220. Ehrnhoefer, D. E.; Bieschke, J.; Boeddrich, A.; Herbst, M.; Masino, L.; Lurz, R.; Engemann, S.; Pastore, A.; Wanker, E. E. EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nat. Struct. Mol. Biol. 15: 558-566; 2008. (Pubitemid 351799141)
221. Bieschke, J.; Russ, J.; Friedrich, R. P.; Ehrnhoefer, D. E.; Wobst, H.; Neuge-bauer, K.; Wanker, E. E. EGCG remodels mature alpha-synuclein and amyloid-beta fibrils and reduces cellular toxicity. Proc. Natl. Acad. Sci. USA 107: 7710-7715; 2010.
222. Solomons, N. W. N., O. M.; Crowley, C; Romero-Abal, M. E.; Schumann, K. Iron: nutrition's two-edged sword. Sight Life 2: 20-24; 2010.
223. Chan, P.; Qin, Z.; Zheng, Z.; Zhang, L.; Fang, X.; Sun, F.; Gu, Z.; Chen, S.; Ma, J.; Meng, C; Langston, J. W.; Tanner, C. M.; Group., C. P. S. A randomized, double-blind, placebo controlled, delayed start study to assess safety, tolerability and efficacy of green tea polyphenols in Parkinson's disease. In XVIII WFN World Congress on Parkinson's Disease and Related Disorders, 13-16 December 2009, Miami Beach; Vol. 15, p. S145.
224. Kupershmidt, L.; Amit, T.; Bar-Am, O.; Youdim, M. B.; Weinreb, O. The novel multi-target iron chelating-radical scavenging compound M30 possesses beneficial effects on major hallmarks of Alzheimer's disease. Antioxid. Redox Signaling 17: 860-877; 2012.
225. Kupershmidt, L; Amit, T.; Bar-Am, O.; Youdim, M. B.; Weinreb, O. Neuroprotection by the multitarget iron chelator M30 on age-related alterations in mice. Mech. Ageing Dev. 133: 267-274; 2012.
226. Kalinowski, D. S.; Richardson, D. R. The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol. Rev. 57: 547-583; 2005. (Pubitemid 43036441)
227. Hanson, L. R.; Roeytenberg, A.; Martinez, P. M.; Coppes, V. G.; Sweet, D. C; Rao, R. J.; Marti, D. L.; Hoekman, J. D.; Matthews, R. B.; Frey 2nd W. H.; Panter, S. S. Intranasal deferoxamine provides increased brain exposure and significant protection in rat ischemic stroke. J. Pharmacol. Exp. Ther. 330: 679-686; 2009.
228. Nick, H.; Wong, A.; Acklin, P.; Faller, B.; Jin, Y.; Lattmann, R.; Sergejew, T.; Hauffe, S.; Thomas, H.; Schnebli, H. P. ICL670A: preclinical profile. Adv. Exp. Med. Biol. 509: 185-203; 2002. (Pubitemid 37526718)
229. Nakagawa, K.; Miyazawa, T. Absorption and distribution of tea catechin, (-) -epigallocatechin-3-gallate, in the rat. J. Nutr. Sci. Vitaminol. (Tokyo) 43: 679-684; 1997. (Pubitemid 28045726)
230. Zheng, H.; Youdim, M. B.; Weiner, L. M.; Fridkin, M. Synthesis and evaluation of peptidic metal chelators for neuroprotection in neurodegenerative diseases. J. Pept. Res. 66: 190-203; 2005.) (Pubitemid 41344612)